More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio

超过60篇摘要，包括15篇口头报告和快速口头报告，展示了辉瑞行业领先的肿瘤学产品组合的进展。

ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI

ASCO新闻计划将介绍BRAFTOVI的总生存期和无进展生存期数据

®

®

(encorafenib) combination regimen in first-line

(encorafenib)联合方案一线治疗

BRAF V600E

BRAF V600E

-mutant metastatic colorectal cancer and progression-free survival data from VERITAC-2 study of vepdegestrant in metastatic breast cancer

-突变型转移性结直肠癌以及VEPDEGESTRANT在转移性乳腺癌VERITAC-2研究中的无进展生存数据

Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs

多项研究表明维多汀抗体药物偶联物（ADCs）与派姆单抗的联合潜力，包括两种首创新ADC在胸部癌症中的首个1期数据。

NEW YORK--(BUSINESS WIRE)--

纽约--（商业资讯）--

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO

辉瑞公司（纽约证券交易所代码：PFE）将在2025年美国临床肿瘤学会（ASCO）上展示其潜在突破性癌症药物组合的多项数据。

®

®

) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary, hematologic, and thoracic cancers, as well as colorectal cancer..

）年度会议，将于5月30日至6月3日在芝加哥举行。辉瑞将在其关键肿瘤领域展示超过60份公司赞助、研究者赞助及合作研究的摘要数据，其中包括9场口头报告和6场快速口头报告，涵盖乳腺癌、泌尿生殖系统癌症、血液癌症、胸部癌症以及结直肠癌等领域。

“This has already been a significant year for Pfizer’s Oncology pipeline, with multiple Phase 3 data readouts and regulatory approvals, and the initiation of pivotal registrational programs across our major tumor areas of focus,” said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research & Development, Pfizer.

“这对辉瑞的肿瘤学管线来说已经是重要的一年，我们获得了多个三期数据读数和监管批准，并在我们主要关注的肿瘤领域启动了关键的注册计划，”辉瑞公司首席科学官兼研发总裁克里斯·博沙夫（Chris Boshoff）医学博士说道。

“The depth and diversity of our data presentations at ASCO are building on that momentum to bring us closer to our goal of delivering eight breakthrough cancer medicines by 2030.”.

“我们在ASCO上的数据展示的深度和多样性正在推动这一势头，使我们更接近到2030年交付八种突破性癌症药物的目标。”

Pfizer will have two late-breaking oral presentations featured in ASCO’s embargoed pre-meeting

辉瑞将在ASCO会前的新闻发布会上发表两项最新的口头报告。

press briefing

新闻发布会

on May 27. These include the primary analysis of the pivotal overall survival (OS) and progression-free survival (PFS) results from the Phase 3 BREAKWATER study investigating BRAFTOVI

5月27日。这些数据包括关键的总生存期（OS）和无进展生存期（PFS）主要分析结果，来自评估BRAFTOVI的III期BREAKWATER研究。

®

®

(encorafenib)

（恩考芬尼）

in combination with cetuximab (marketed as ERBITUX

与西妥昔单抗（商品名：ERBITUX）联合使用

®

®

) and mFOLFOX6 in patients with

`) 和 mFOLFOX6 在患者中`

BRAF V600E

BRAF V600E突变

-mutant metastatic colorectal cancer,* as well as the first presentation of the PFS results from the Phase 3 VERITAC-2 study of vepdegestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (a/mBC) in partnership with Arvinas.**.

-突变型转移性结直肠癌，* 以及与Arvinas合作的3期VERITAC-2研究中vepdegestrant用于雌激素受体阳性、人表皮生长因子受体2阴性（ER+/HER2-）晚期或转移性乳腺癌（a/mBC）患者的PFS结果的首次展示。**。

Pfizer will share additional updates from key late-stage programs, including five-year survival data from the Phase 3 ARCHES study of XTANDI

辉瑞将分享来自关键后期项目的新进展，包括XTANDI的三期ARCHES研究的五年生存数据。

®

®

(enzalutamide) in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHPSC),*** and the first combination data for ELREXFIO

（恩杂鲁胺）与雄激素剥夺疗法联合用于转移性激素敏感性前列腺癌 (mHPSC)，以及ELREXFIO的首个组合数据

®

®

(elranatamab) + daratumumab + lenalidomide from the ongoing MagnetisMM-6 study in patients with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).

（elranatamab）+ daratumumab + lenalidomide 来自正在进行的 MagnetisMM-6 研究，适用于不符合移植条件 (TI) 的新诊断多发性骨髓瘤 (NDMM) 患者。

Pfizer will also share new findings highlighting the company’s strategy to explore novel vedotin antibody-drug conjugates (ADCs) in combination with immune checkpoint inhibitors to potentially enhance anti-tumor activity. For the first time, Pfizer will present encouraging Phase 1 data on two novel investigational ADCs in combination with pembrolizumab in thoracic cancers: sigvotatug vedotin (SV), an integrin beta-6 (IB6)-directed ADC, in lung cancer and head and neck cancers, and PDL1V (PF-08046054), a PD-L1 directed ADC, in head and neck cancers.

辉瑞还将分享新的研究结果，突出该公司探索新型维多汀抗体-药物偶联物（ADCs）与免疫检查点抑制剂联合使用的战略，以潜在增强抗肿瘤活性。辉瑞将首次展示两项新型在研ADC与派姆单抗联合用于胸部癌症的1期试验鼓舞人心的数据：sigvotatug vedotin（SV），一种针对整合素β-6（IB6）的ADC，用于肺癌和头颈癌；以及PDL1V（PF-08046054），一种针对PD-L1的ADC，用于头颈癌。

Additionally, new exploratory analyses will be presented from the pivotal EV-302 trial with PADCEV.

此外，来自关键的EV-302试验的新探索性分析将会被展示。

®

®

(enfortumab vedotin) in combination with KEYTRUDA

(enfortumab vedotin)联合KEYTRUDA

®

®

(pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).****

(pembrolizumab)用于既往未接受治疗的局部晚期或转移性尿路上皮癌（la/mUC）患者。

Several presentations will highlight updated results from ongoing Phase 1 studies that inform the dosing strategy in registrational programs for two molecules targeting epigenetic regulators: mevrometostat, an investigational EZH2 inhibitor being evaluated in combination with XTANDI for metastatic castration-resistant prostate cancer (mCRPC); and PF-07248144, a potential first-in-class KAT6 inhibitor for ER+/HER2- metastatic breast cancer (mBC)..

几项报告将重点介绍正在进行的I期研究的最新结果，这些结果为两种针对表观遗传调节因子的分子在注册项目中的剂量策略提供了信息：一种是正在评估与XTANDI联合用于转移性去势抵抗性前列腺癌（mCRPC）的试验性EZH2抑制剂mevrometostat；另一种是PF-07248144，一种潜在的首创KAT6抑制剂，用于ER+/HER2-转移性乳腺癌（mBC）。

“Our data at ASCO this year reflect how we are strategically progressing our deep pipeline of next generation cancer medicines while simultaneously extending the impact of our foundational therapies to reach more people living with cancer,” said Megan O’Meara, Head of Early-Stage Development and Interim Head of Late-Stage Development, Pfizer Oncology.

“我们在今年ASCO公布的数据反映了我们如何战略性地推进下一代癌症药物的深度研发，同时扩展我们基础疗法的影响力，以惠及更多癌症患者，”辉瑞肿瘤学早期开发负责人兼晚期开发临时负责人梅根·奥米拉表示。

“Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal Phase 3 trials this year.”.

“重要的早期更新突显了我们在核心癌症类型中的广泛管线和深度，因为我们今年将推进多达九个新的关键性III期试验。”

Key ASCO Presentations

ASCO重要报告

Colorectal Cancers

结直肠癌

BRAFTOVI

康奈非尼

: A late-breaking session will detail PFS and OS results from the Phase 3 BREAKWATER study of BRAFTOVI in combination with cetuximab and mFOLFOX6 chemotherapy in

：一个最新的会议将详细介绍BRAFTOVI与西妥昔单抗和mFOLFOX6化疗联合使用在第三阶段BREAKWATER研究中的PFS和OS结果。

BRAF V600E

BRAF V600E突变

-mutant metastatic colorectal cancer, further establishing the benefit of the BRAFTOVI combination regimen following its FDA accelerated approval in late 2024. These pivotal study results follow the

-突变型转移性结直肠癌，进一步证实了BRAFTOVI联合治疗方案在其于2024年底获得FDA加速批准后的益处。这些关键研究结果紧随其后。

topline results announcement

顶线结果公告

for PFS and OS and the objective response rate (ORR) results

针对PFS和OS以及客观缓解率（ORR）结果

presented at ASCO GI

在ASCO GI上发表

. These new data will also be featured in the ASCO press program.

这些新数据还将在ASCO新闻计划中重点介绍。

Breast Cancer

乳腺癌

Vepdegestrant

维帕地斯特兰

: In a late-breaking session, PFS data will be presented for the first time from the Phase 3 VERITAC-2 study of vepdegestrant, a PROTAC ER degrader, in ER+/HER2− a/mBC. These detailed data follow the

在一场最新的会议中，将首次展示来自vepdegestrant（一种PROTAC ER降解剂）的3期VERITAC-2研究的无进展生存期数据，针对ER+/HER2− a/mBC患者。这些详细数据如下：

topline results from VERITAC-2

VERITAC-2 的主要结果

announced earlier this year and will also be featured in the ASCO press program.

在今年早些时候宣布，并且也将被纳入ASCO新闻计划中。

PF-07248144 (KAT6 inhibitor)

PF-07248144（KAT6抑制剂）

: A rapid oral presentation will highlight dose optimization data from an ongoing Phase 1 study for PF-07248144, a potential first-in-class KAT6 inhibitor, in patients with ER+/HER2− mBC. These results support the recommended dosing for PF-07248144 ahead of the Phase 3 trial initiation in second-line mBC planned for 2H 2025..

：一项快速口头报告将重点介绍PF-07248144（一种潜在的首创KAT6抑制剂）在ER+/HER2− mBC患者中的正在进行的1期研究的剂量优化数据。这些结果支持在计划于2025年下半年启动的二线mBC的3期试验之前，为PF-07248144推荐剂量。

IBRANCE

哌柏西利

®

®

(palbociclib)

（帕博西尼）

: Roche will present detailed results from the OS analysis of the Phase 3 INAVO120 study investigating ITOVEBI™ (inavolisib) in combination with IBRANCE and fulvestrant in patients with

罗氏将展示INAVO120三期研究的OS分析详细结果，该研究调查了ITOVEBI™（inavolisib）与IBRANCE和氟维司群联合用于患者的治疗效果。

PIK3CA

PIK3CA

-mutated, HR+/HER2-, endocrine-resistant, locally a/mBC. This presentation will be featured in ASCO’s embargoed pre-meeting

-突变型、HR+/HER2-、内分泌耐药、局部晚期或转移性乳腺癌。该报告将在ASCO会议前的禁运预会议中展示。

press briefing

新闻简报

on May 21.

5月21日。

Genitourinary Cancers

泌尿生殖系统癌症

XTANDI

恩杂鲁胺

: Five-year follow-up overall survival data from the ARCHES study of XTANDI in combination with androgen deprivation therapy in patients with mHSPC will be featured in an oral presentation. In addition, updates from the Astellas-supported, investigator-sponsored ENZAMET Phase 3 research study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and sponsored by the University of Sydney, will also be presented, including 8 year-outcomes in men with mHSPC.

：ARCHES 研究中关于 XTANDI 联合雄激素剥夺疗法在 mHSPC 患者中的五年随访总生存数据将在口头报告中展示。此外，由 Astellas 支持、研究者发起的 ENZAMET 第三阶段研究更新也将被公布，该研究由澳大利亚和新西兰泌尿生殖与前列腺癌试验组 (ANZUP) 领导并由悉尼大学赞助，内容包括 mHSPC 男性患者的八年结果。

These presentations further underscore the value of XTANDI across approved indications..

这些报告进一步强调了XTANDI在获批适应症中的价值。

Mevrometostat

美夫罗莫司他

: A poster presentation will highlight pharmacokinetic and safety data from the ongoing Phase 1 study for mevrometostat, an investigational EZH2 inhibitor, in combination with XTANDI. These updated data further inform the dosing strategy for mevrometostat in a robust registrational program that includes two Phase 3 trials in mCRPC, and a third trial in metastatic castration-sensitive prostate cancer (mCSPC) that is planned to start in 1H 2025..

：一张海报展示将突出介绍正在开展的 mevrometostat（一种研究中的 EZH2 抑制剂）1 期研究的药代动力学和安全性数据，该研究与 XTANDI 联合使用。这些更新的数据进一步明确了 mevrometostat 在一个强大的注册计划中的剂量策略，其中包括两项针对 mCRPC 的 3 期试验，以及计划于 2025 年上半年启动的针对转移性去势敏感性前列腺癌（mCSPC）的第三项试验。

PADCEV

帕德维（PADCEV）

: Additional updates from the Phase 3 EV-302 study of PADCEV in combination with KEYTRUDA in previously untreated la/mUC will be presented, including an oral presentation with exploratory analysis of responders.

：PADCEV联合KEYTRUDA用于既往未治疗的la/mUC的3期EV-302研究的更多更新数据将会公布，其中包括一份关于应答者探索性分析的口头报告。

Hematologic Cancers

血液癌症

ELREXFIO

ELREXFIO

: Initial safety and efficacy results from Part 1 of the ongoing MagnetisMM-6 study of ELREXFIO in combination with daratumumab and lenalidomide in patients with newly diagnosed MM that are not eligible for transplant will be presented as an oral presentation. Part 1 of the ongoing MagnetisMM-6 study evaluates the optimal dose of the ELREXFIO combination regimen in patients with RRMM or NDMM to determine the recommended phase 3 dose for part 2..

：正在进行的MagnetisMM-6研究第一部分的初步安全性和有效性结果，将作为口头报告展示。该研究评估了ELREXFIO联合达拉图单抗和来那度胺在不符合移植条件的新诊断多发性骨髓瘤（MM）患者中的应用。MagnetisMM-6研究的第一部分旨在评估ELREXFIO联合方案在复发/难治性多发性骨髓瘤（RRMM）或新诊断多发性骨髓瘤（NDMM）患者中的最佳剂量，以确定第二部分推荐的第三阶段剂量。

Thoracic Cancers

胸腔癌症

Sigvotatug vedotin (SV):

西格沃塔图格 韦多汀 (SV):

Phase 1 results for SV, an IB6-directed vedotin ADC, in combination with pembrolizumab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) will be featured in a rapid oral presentation. This initial combination data for SV with pembrolizumab support a Phase 3 study in first line PD-L1-High NSCLC, initiated this year.

SV是一种针对IB6的vedotin抗体药物偶联物（ADC），其与pembrolizumab联合用于非小细胞肺癌（NSCLC）和头颈部鳞状细胞癌（HNSCC）的I期结果将在一场快速口头报告中展示。SV与pembrolizumab的这一初步联合数据显示出在PD-L1高表达的初治NSCLC中开展III期研究的潜力，该研究已于今年启动。

The data also support the overall SV trial program that includes an ongoing Phase 3 monotherapy trial in second line+ NSCLC..

数据还支持了整体的SV试验项目，其中包括一个正在进行的针对二线及以上非小细胞肺癌的三期单药治疗试验。

PDL1V (PF-08046054)

PDL1V（PF-08046054）

: Two poster presentations will highlight interim Phase 1 results for PDL1V, a PD-L1 directed vedotin ADC, as monotherapy in NSCLC and initial safety and efficacy data in combination with pembrolizumab in patients with first-line recurrent or metastatic (r/m) HNSCC. These data provide additional support for the initiation of the two pivotal Phase 3 trials planned for PDL1V in 2025 in second line+ NSCLC and first line r/mHNSCC..

两份海报展示将重点介绍PDL1V的中期第一阶段结果，PDL1V是一种针对PD-L1的vedotin抗体药物偶联物（ADC），作为单药治疗非小细胞肺癌（NSCLC）以及与pembrolizumab联合使用的初步安全性和有效性数据，用于一线复发或转移性头颈鳞状细胞癌（r/m HNSCC）患者。这些数据为计划于2025年开展的两项关键第三阶段试验（针对二线及以上NSCLC和一线r/m HNSCC的PDL1V试验）提供了进一步支持。

Additional information on key Pfizer-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer-sponsored accepted abstracts is

以下是关于辉瑞公司赞助的关键摘要的更多信息，包括演讲的日期和时间。完整的辉瑞公司赞助的已接受摘要列表如下。

available here

这里可用

.

。

Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ASCO, which are written in non-technical language. Those interested in learning more can visit .

辉瑞公司继续致力于帮助非科学家理解最新的研究成果，正在为在ASCO上展示的公司赞助研究开发摘要通俗语言总结（APLS），这些总结以非技术性语言撰写。有兴趣了解更多的人可以访问。

www.Pfizer.com/apls

www.Pfizer.com/apls

to access the summaries starting May 22, 2025.

要访问从2025年5月22日开始的摘要。

COLORECTAL CANCERS

结直肠癌

Oral Presentation (Abstract LBA3500)

口头报告（摘要编号 LBA3500）

Friday, May 30, 2:45-5:45 PM CDT

5月30日星期五，下午2:45-5:45（中部夏令时间）

First-line encorafenib + cetuximab + mFOLFOX6 in

一线治疗使用Encorafenib + Cetuximab + mFOLFOX6

BRAF V600E

BRAF V600E

-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses

-突变型转移性结直肠癌（BREAKWATER）：无进展生存期和更新的总生存期分析

Elez et al

埃莱兹等人

BREAST CANCER

乳腺癌

Rapid Oral Presentation (Abstract 1020)

快速口头报告（摘要1020）

Friday, May 30, 2:45-4:15 PM CDT

5月30日星期五，下午2:45-4:15（中部夏令时）

Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D)

PF-07248144（一种首创的KAT6抑制剂）在ER+/HER2−转移性乳腺癌（mBC）患者中的剂量优化：支持推荐的3期剂量（RP3D）的1期研究结果

LoRusso et al

洛鲁索等

Oral Presentation (Abstract LBA1000)

口头报告（摘要编号 LBA1000）

Saturday, May 31, 1:15-4:15 PM CDT

5月31日星期六，下午1:15-4:15（北美中部夏令时间）

Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study

VEPDEGESTRANT，一种PROTAC雌激素受体（ER）降解剂，与氟维司群在ER阳性/人表皮生长因子受体2（HER2）阴性晚期乳腺癌中的比较：全球随机3期VERITAC-2研究结果

Hamilton et al

汉密尔顿等

GENITOURINARY CANCERS

泌尿生殖系统癌症

Oral Presentation (Abstract 4502)

口头报告（摘要4502）

Sunday, June 1, 9:45 AM-12:45 PM CDT

6月1日，星期日，上午9点45分至下午12点45分（中部夏令时间）

Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)

对来自 enfortumab vedotin 加 pembrolizumab（EV+P）与化疗（chemo）在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中的 3 期 EV-302 试验的应答者进行探索性分析

Gupta et al

古普塔等

Oral Presentation (Abstract 5005)

口头报告（摘要5005）

Tuesday, June 3, 9:45 AM-12:45 PM CDT

6月3日星期二，上午9:45至下午12:45（中部夏令时间）

ARCHES 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

ARCHES 5年随访总生存期（OS）分析：恩扎鲁胺（ENZA）联合雄激素剥夺疗法（ADT）治疗转移性激素敏感性前列腺癌（mHSPC）患者（pts）

Armstrong et al

阿姆斯特朗等

Poster Presentation (Abstract 4571)

海报展示（摘要4571）

Monday, June 2, 9:00 AM-12:00 PM CDT

6月2日星期一，上午9:00-12:00（中部夏令时间）

EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)

EV-302：来自恩福妥单抗 vedotin 联合帕博利珠单抗（EV+P）与化疗（chemo）在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中的全球 III 期研究的长期亚组分析

Bedke et al

贝德克等人

Poster Presentation (Abstract 5046)

海报展示（摘要5046）

Monday, June 2, 9:00 AM-12:00 PM CDT

6月2日星期一，上午9:00-12:00（中部夏令时间）

Safety and pharmacokinetics of mevrometostat (M) in combination with enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC)

在转移性去势抵抗性前列腺癌（mCRPC）患者中，美伐莫司他（M）与恩杂鲁胺（E）联合使用的安全性和药代动力学研究

Matsubara et al

松原等人

HEMATOLOGIC CANCERS

血液系统癌症

Oral Presentation (Abstract 7504)

口头报告（摘要7504）

Tuesday, June 3, 9:45 AM-12:45 PM CDT

6月3日星期二，上午9点45分至下午12点45分（中部夏令时间）

Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1

Elranatamab联合达拉图单抗和来那度胺（EDR）治疗新诊断的不符合移植条件的多发性骨髓瘤（NDMM）患者：MagnetisMM-6第一部分初步结果

Quach et al

Quach 等人

THORACIC CANCERS

胸腔癌症

Rapid Oral Presentation (Abstract 3010)

快速口头报告（摘要3010）

Monday, June 2, 8:00-9:30 AM CDT

6月2日星期一，上午8:00-9:30（中部夏令时间）

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001)

西格沃塔图格韦多汀（SV），一种研究性的整合素β-6（IB6）导向的抗体-药物偶联物（ADC），与派姆单抗联合疗法：来自正在进行的1期研究（SGNB6A-001）的初步结果

Sehgal et al

Sehgal等人

Poster Presentation (Abstract 6033)

海报展示（摘要6033）

Monday, June 2, 9:00 AM-12:00 PM CDT

6月2日星期一，上午9:00-12:00（中部夏令时间）

Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC

PDL1V（PF-08046054），一种靶向PD-L1的vedotin类ADC，与pembrolizumab联合用于复发或转移性（R/M）头颈部鳞状细胞癌（HNSCC）患者的初步安全性和有效性研究

Gillison et al

吉里森等

Poster Presentation (Abstract 8611)

海报展示（摘要8611）

Saturday, May 31, 1:30-4:30 PM CDT

5月31日星期六，下午1:30-4:30（中部夏令时间）

Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial

PDL1V（PF-08046054），一种针对PD-L1的vedotin类ADC，在1期试验中针对非小细胞肺癌（NSCLC）患者的中期结果

Fontana et al

方塔纳等

*The BREAKWATER trial was conducted with support from ONO Pharmaceutical, Merck KGaA, Darmstadt, Germany and Eli Lilly and Company.

*防波堤试验是在小野制药、德国达姆施塔特的默克KGaA以及礼来公司的支持下进行的。

**Pfizer and Arvinas have a global collaboration for the co-development and co-commercialization of vepdegestrant.

辉瑞和Arvinas在全球范围内合作，共同开发和商业化vepdegestrant。

***XTANDI

***恩杂鲁胺

®

®

is jointly developed and commercialized by Pfizer and Astellas in the United States.

在美国，由辉瑞和安斯泰来共同开发和商业化。

****Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV

辉瑞和安斯泰来与默克公司达成了一项临床合作协议，以评估PADCEV的组合疗法。

®

®

and KEYTRUDA

和KEYTRUDA

®

®

in patients with previously untreated metastatic urothelial cancer.

在既往未治疗的转移性尿路上皮癌患者中。

Prescribing Information for Pfizer Medicines

辉瑞药品的处方信息

Please see full

请看完整内容

Prescribing Information

处方信息

for BRAFTOVI

适用于BRAFTOVI

®

®

.

。

Please see full

请看完整内容

Prescribing Information

处方信息

, including BOXED WARNING, for ELREXFIO™ (elranatamab-bcmm).

，包括加框警告，适用于ELREXFIO™（elranatamab-bcmm）。

Please see full Prescribing Information for IBRANCE

请参阅 IBRANCE 的完整处方信息

®

®

(palbociclib)

(帕博西尼)

tablets

平板电脑

and IBRANCE

和IBRANCE

®

®

(palbociclib)

（帕博西尼）

capsules

胶囊

.

。

Please see full

请查看完整内容

Prescribing Information

处方信息

, including BOXED WARNING, for PADCEV

，包括PADCEV的加框警告，

®

®

(enfortumab vedotin).

（恩福妥单抗 vedotin）。

Please see full

请查看完整内容

Prescribing Information

处方信息

for XTANDI

适用于XTANDI

®

®

(enzalutamide).

（恩杂鲁胺）。

About Pfizer Oncology

辉瑞肿瘤学概况

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics.

在辉瑞肿瘤学，我们正处于癌症治疗新时代的前沿。我们行业领先的资产组合和广泛的管线包括三种核心作用机制，从多个角度攻击癌症，包括小分子、抗体药物偶联物 (ADC)、双特异性抗体，以及其他免疫肿瘤学生物制剂。

We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives..

我们专注于在一些全球最常见的癌症领域提供变革性的治疗方法，包括乳腺癌、泌尿生殖系统癌症、血液肿瘤学以及胸部癌症（包括肺癌）。在科学的驱动下，我们致力于加速突破，帮助癌症患者过上更好、更长寿的生活。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破性进展

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们运用科学和全球资源，为人们带来能够延长生命并显著改善生活的疗法。我们致力于在医疗保健产品的研发、开发和生产过程中，树立质量、安全和价值的标杆，包括创新药物和疫苗。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

每天，辉瑞的同事们在发达市场和新兴市场开展工作，推动健康、预防、治疗和攻克当今最令人恐惧的疾病。作为全球首屈一指的创新型生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持并扩大全球范围内可靠、负担得起的医疗保健服务的可及性。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at .

175年来，我们一直努力为所有依赖我们的人带来改变。我们经常在我们的网站上发布可能对投资者重要的信息。

www.pfizer.com

www.pfizer.com

. In addition, to learn more, please visit us on

此外，欲了解更多，请访问我们

www.pfizer.com

www.pfizer.com.cn

and follow us on X at

并在X上关注我们

@Pfizer

@辉瑞

and

和

@Pfizer_News

@辉瑞新闻

,

，

LinkedIn

领英

,

，

YouTube

YouTube

and like us on Facebook at

并在 Facebook 上关注我们

Facebook.com/Pfizer

Facebook.com/辉瑞

.

。

Disclosure Notice

披露通知

The information contained in this release is as of April 23, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

本新闻稿中的信息截至2025年4月23日。辉瑞不对因新信息或未来事件或发展而更新本新闻稿中包含的前瞻性声明承担任何义务。

This release contains forward-looking information about Pfizer Oncology and Pfizer’s oncology portfolio of marketed and investigational therapies, including their potential benefits; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications or combinations, including expected clinical trial protocols, the potential and timing for the initiation and progress of clinical trials and data read-outs from trials; the timing and potential for the submission of applications for and receipt of regulatory approvals; the timing and potential for product launches and commercialization; expected breakthrough, best- or first-in-class or blockbuster status or expected market entry of our medicines; potential patients reached; the regulatory landscape; the competitive landscape; and other statements about our business, operations and financial results that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

本发布包含有关辉瑞肿瘤学部门及其已上市和研究中的肿瘤治疗产品组合的前瞻性信息，包括其潜在益处；对我们产品管线、在售产品及候选产品的预期，包括预计的监管提交、数据解读、研究启动、批准、上市、临床试验结果及其他发展中的数据；我们产品管线、在售产品、候选产品以及额外适应症或组合的研发或商业化潜力，包括预期的临床试验方案、临床试验启动与进展的潜力和时间安排以及试验数据的解读；申请提交及获得监管批准的时机与潜力；产品上市及商业化的时机与潜力；预期的突破性、同类最佳或首创地位或预期的药品市场进入；潜在患者覆盖范围；监管环境；竞争格局；以及其他涉及我们业务、运营和财务结果的声明，这些声明包含重大风险和不确定性，可能导致实际结果与此类声明中明示或暗示的结果存在重大差异。

Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s oncology portfolio; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risk.

风险和不确定性包括，除其他事项外，关于辉瑞肿瘤学产品组合商业成功的不确定性；研发中固有的不确定性，包括达到预期临床终点的能力、我们临床试验的启动和/或完成日期、监管提交日期、监管批准日期和/或上市日期，以及出现不利的新临床数据和对现有临床数据进一步分析的可能性；风险。

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S.

辉瑞公司截至2024年12月31日的财政年度的10-K表格年度报告及其后续的10-Q表格报告中，特别是在标题为“风险因素”和“前瞻性信息及可能影响未来结果的因素”的章节中，以及其后续的8-K表格报告中，均可找到更多关于风险和不确定性的描述，所有这些文件均已提交给美国证券交易委员会。

Securities and Exchange Commission and available at .

证券交易委员会，可访问。

www.sec.gov

www.sec.gov

and

和

www.pfizer.com

www.pfizer.com

.

。

Media Contact:

媒体联系人：

+1 (212) 733-1226

+1 (212) 733-1226

PfizerMediaRelations@Pfizer.com

辉瑞媒体关系@辉瑞.com

Investor Contact:

投资者联系方式：

+1 (212) 733-4848

+1 (212) 733-4848

IR@Pfizer.com

IR@Pfizer.com

Source: Pfizer Inc.

来源：辉瑞公司